U.S. Prosthetic Heart Valve Market By Product (Tissue Heart Valve, Mechanical Heart Valve, Transcatheter Heart Valve) , : Opportunity Analysis and Industry Forecast, 2024-2033
The U.S. prosthetic heart valve market was valued at $3.2 billion in 2023, and is projected to reach $8.9 billion by 2033, growing at a CAGR of 10.7% from 2024 to 2033.
Prosthetic heart valve is a medical device implanted in the heart to replace a diseased or damaged valve that cannot regulate blood flow effectively. These artificial valves are designed to mimic the function of natural heart valves, ensuring proper one-way blood flow through the heart and preventing leakage. Prosthetic heart valves are primarily used to treat conditions such as valve stenosis (narrowing) or valve regurgitation (leakage), which can compromise heart function and overall health.
The growth of the U.S. prosthetic heart valve market is driven by alarming rise in the prevalence of cardiovascular conditions such as aortic stenosis and mitral regurgitation. According to a study published by the Centers for Disease Control and Prevention in 2024, heart disease is the leading cause of death in the U.S., resulting in 702,880 deaths in 2022. The study further highlighted that one individual dies every 33 seconds due to cardiovascular disease. This highlights the urgent need for prosthetic heart valves, thus augmenting the market growth. In addition, surge in geriatric population significantly contributes toward the market growth. This is attributed to the fact that this demographic has a higher susceptibility to heart valve degeneration. As per the 2024 data recorded by the Population Reference Bureau, the number of Americans aging 65 years and older was 58 million in 2022, and is estimated to reach 82 million by 2050. Furthermore, increase in awareness of screening programs acts as the key driving force of the market. For instance, the Million Hearts® is a national initiative co-led by the Centers for Disease Control and Prevention, which focuses on preventing 1 million heart attacks and strokes within 5 years. Moreover, rise in adoption of minimally invasive procedures and supportive reimbursement policies strengthen the market growth. However, high costs of prosthetic valves and procedures acts as the key deterrent factor of the market. In addition, risk of post-surgical complications such as thrombosis, structural valve degeneration, and endocarditis restrains the market growth. On the contrary, innovations such as transcatheter aortic valve replacement have revolutionized treatment, offering minimally invasive options for patients who are high-risk for open-heart surgery. Such developments are expected to offer lucrative opportunities for the expansion of the market during the forecast period.
The U.S. prosthetic heart valve market is segmented on the basis of product. By product, the market is categorized into mechanical heart valve, tissue heart valve, and transcatheter heart valve. The tissue heart valve segment is further classified into stented tissue heart valve and stent less tissue heart valve.
Key FindingsThe transcatheter heart valve segment generated the largest revenue in U.S. prosthetic heart valve market share in 2023, and is expected to continue the same trend from 2024 to 2033.
Competition AnalysisCompetitive analysis and profiles of the major players in the global U.S. prosthetic heart valve market include Abbott Laboratories, Artivion, Inc, Anteris Technologies Ltd, Boston Scientific Corporation, Edward Lifesciences Corporation, JenaValve Technology, Inc., Colibri Heart Valve, Medtronic plc, Meril Life Sciences Pvt. Ltd., and ShockWave Medical, Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the competitive market.
Key Market SegmentsBy ProductTissue Heart Valve
Stented Tissue Heart Valve
Stentless Tissue Heart Valve
Mechanical Heart Valve
Transcatheter Heart Valve
Key Market PlayersAbbott Laboratories
Artivion, Inc
Anteris Technologies Ltd
Boston Scientific Corporation
Edward Lifesciences Corporation
JenaValve Technology, Inc.
Colibri Heart Valve
Medtronic plc
Meril Life Sciences Pvt. Ltd.
ShockWave Medical, Inc.